本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

PharmaCyte Biotech, Inc.

0.9390
-0.0210-2.19%
盘后0.94300.0040+0.43%19:28 EDT
成交量:3.35万
成交额:3.17万
市值:638.12万
市盈率:0.29
高:0.9700
开:0.9618
低:0.9250
收:0.9600
52周最高:2.42
52周最低:0.8000
股本:679.58万
流通股本:607.75万
量比:0.79
换手率:0.55%
股息:- -
股息率:- -
每股收益(TTM):3.19
每股收益(LYR):3.19
净资产收益率:67.08%
总资产收益率:-4.76%
市净率:0.12
市盈率(LYR):0.29

数据加载中...

2025/08/18

重要事件披露

Form 8-K - Current report
2025/08/09

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/04/24

重要事件披露

Form 8-K - Current report
2025/03/17

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2025/02/26

重要事件披露

Form 8-K - Current report
2024/12/13

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/12/04

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/13

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/17

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/08/13

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/05/31

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/02

重要事件披露

Form 8-K - Current report
2024/03/18

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/06

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/12/16

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/25

重要事件披露

Form 8-K - Current report
2023/11/23

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2023/11/16

重要事件披露

Form 8-K - Current report